Related Experiment Video

Updated: Aug 30, 2025

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

7.7K

The Features of Immune Checkpoint Gene Regulation by microRNA in Cancer

Fatimat Kipkeeva1, Tatyana Muzaffarova1, Alexandra Korotaeva1

  • 1Research Centre for Medical Genetics, 1 Moskvorechye St., 115522 Moscow, Russia.

International Journal of Molecular Sciences
|August 26, 2022
PubMed

Insights

MicroRNAs (miRNAs) show promise for cancer immunotherapy by regulating immune checkpoints. While many miRNAs are tumor-specific, some effectively target multiple checkpoints, suggesting potential for combination therapies.

Area of Science:

  • Immunology
  • Molecular Biology
  • Oncology

Background:

  • Immunotherapy is a key area in cancer treatment, with ongoing research for novel therapeutic tools.
  • MicroRNAs (miRNAs) are emerging as critical regulators of immune cells, influencing gene expression.
  • miRNAs impact immune checkpoint (IC) gene expression in tumor and T-cells, crucial for immune response modulation.

Purpose of the Study:

  • To identify microRNAs that simultaneously regulate multiple immune checkpoints.
  • To explore miRNAs that can target both immune checkpoints and genes relevant to targeted cancer therapy.
  • To analyze the tumor specificity of miRNA interactions with immune checkpoint genes.

Main Methods:

  • Literature review and data analysis of miRNA interactions with immune checkpoint genes.
  • Identification of miRNAs affecting multiple ICs and targeted therapy genes.
  • Assessment of miRNA efficacy in vitro and in vivo.

Main Results:

  • A list of miRNAs acting on multiple ICs and targeted therapy genes was compiled.
  • miRNA regulation of IC genes exhibits significant tumor specificity, with only ~14% affecting ICs in multiple cancer types.
  • Several miRNAs demonstrated high efficacy in preclinical studies (in vitro and in vivo).

Conclusions:

  • MicroRNAs hold significant potential as agents for cancer immunotherapy due to their ability to regulate gene expression.
  • The tumor-specific action of miRNAs on ICs suggests tailored therapeutic strategies.
  • Further research into miRNA-gene interactions and optimal mimic design is warranted for clinical translation.
Keywords:
immune checkpointimmunotherapymicroRNA

More Related Videos

An In Vitro Protocol for Evaluating MicroRNA Levels, Functions, and Associated Target Genes in Tumor Cells09:45

An In Vitro Protocol for Evaluating MicroRNA Levels, Functions, and Associated Target Genes in Tumor Cells

Published on: May 21, 2019

8.4K
CRISPR Gene Editing Tool for MicroRNA Cluster Network Analysis10:40

CRISPR Gene Editing Tool for MicroRNA Cluster Network Analysis

Published on: April 25, 2022

2.5K

Related Concept Videos

MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.1K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
7.9K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR...
2.1K
Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.2K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K